SCHEMBL25041388

SCHEMBL25041388

NC1CCC(Nc2ccc(-n3cccn3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRA P16234 1/20 0.54
▸ SYK P43405 2/20 0.51
▸ CCNE1 P24864 2/20 0.47
▸ CDK2 P24941 2/20 0.47
▸ CDK1 P06493 1/20 0.47
▸ CCNE2 O96020 1/20 0.46
▸ CCNA2 P20248 1/20 0.46
▸ CCNA1 P78396 1/20 0.46
▸ NOTUM Q6P988 1/20 0.45
▸ ADORA2A P29274 3/20 0.44
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ DRD2 P14416 1/20 0.39
▸ DRD4 P21917 1/20 0.39
▸ DRD3 P35462 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ TNIK Q9UKE5 2/20 0.38
▸ MAPK8 P45983 1/20 0.38
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7837578 0.87 NOTUM (0.49) PDGFRASYKCCNE1CDK2CDK1
SCHEMBL29218636 0.80 SYK (0.54) PDGFRASYKNOTUMADORA2AKDM4E
SCHEMBL13438652 0.80 ADORA2A (0.47) PDGFRASYKCCNE1CDK2CDK1
SCHEMBL13462588 0.80 ADORA2A (0.47) PDGFRASYKCCNE1CDK2CDK1
SCHEMBL3528724 0.77 CDK2 (0.63) PDGFRASYKCCNE1CDK2CDK1
SCHEMBL5486439 0.77 CDK2 (0.63) PDGFRASYKCCNE1CDK2CDK1
SCHEMBL25042175 0.75 GPR119 (0.48) SYKALDH1A1MAPK1DRD2DRD3
SCHEMBL29218745 0.74 AKT1 (0.47) PDGFRASYKCCNE1CDK2CDK1
SCHEMBL28205331 0.73 NOTUM (0.58) SYKNOTUMKDM4EALDH1A1MAPK1
SCHEMBL4341894 0.72 NOTUM (0.78) NOTUMKDM4EALDH1A1MAPK1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360114-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2024-10-31 — — US disclosed
EP-4384493-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2024-06-19 — — EP disclosed
WO-2023016447-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2023-02-16 — — WO disclosed
WO-2023016447-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360114-A1 FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF AIFM2, GPX1, GPX4 PDGFRA 3891/4885SYK 4396/4885CCNE1 4136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback